HMBME (4-hydroxy-3-methoxybenzoic acid methyl ester) was developed to target the Akt/NF-κB signaling pathway and was able to inhibit the proliferation of human and mouse PCA cells by reducing phosphorylated Akt and its kinase activity, transcriptional activity of NF-κB and its DNA binding activity, as well as p65 expression. Here, AKT1 is linked to posterior cortical atrophy.